<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Symptomatic management of nephrotic syndrome in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Symptomatic management of nephrotic syndrome in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Symptomatic management of nephrotic syndrome in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Niaudet, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tej K Mattoo, MD, DCH, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 27, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The nephrotic syndrome (NS) is caused by renal diseases that increase the permeability across the glomerular filtration barrier. It is classically characterized by nephrotic-range proteinuria, hypoalbuminemia, and edema. The first two features are diagnostic.
        </p>
        <p>
         Idiopathic NS is the most common form of NS in children, representing more than 90 percent of cases before 10 years of age and 50 percent after 10 years of age. The majority of children with NS will respond to steroid therapy. However, symptomatic treatment is important in the early course of therapy as response to steroid therapy may take several weeks [
         <a href="#rid1">
          1,2
         </a>
         ]. Symptomatic treatment also becomes the mainstay of therapy in children who fail to respond to steroids, especially in those with genetic mutations that cause their NS [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The symptomatic management of NS in children will be reviewed here. Specific treatment of NS in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3533431109">
         <span class="h1">
          HYPOVOLEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite a total increase in body water, children with NS may have a decreased intravascular volume. Serious intravascular volume depletion may be observed at onset of the NS with severe hypoalbuminemia and may be aggravated by diarrhea or diuretics. Clinical signs and symptoms may be present in patients with significant intravascular volume depletion including tachycardia, findings of peripheral vasoconstriction (eg, cool extremities and delayed capillary refill), oliguria, and abdominal pain. A very low fractional excretion of sodium (FENa) less than 0.2 percent is suggestive of volume depletion [
         <a href="#rid4">
          4,5
         </a>
         ]. In this situation, an albumin infusion can be safely administered if clinically required.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EDEMA
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Salt restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Edema is treated by salt restriction because renal retention of sodium is one of two principal mechanisms that lead to edema in the NS. Dietary salt intake should be restricted to less than 2 to 3 mEq/kg per day. In an already edematous patient, salt restriction alone will not significantly improve edema, but can reduce further accumulation of fluid. (See
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome", section on 'Evidence supporting primary renal sodium retention'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Diuretics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We decide whether and how to give diuretics based on the severity of edema and the intravascular volume status of the child.
        </p>
        <p class="headingAnchor" id="H3752831323">
         <span class="h3">
          Patients with severe edema and normal or increased intravascular volume
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe edema and normal or increased intravascular volume (ie, FENa &gt;0.2 percent), we treat with diuretics alone [
         <a href="#rid4">
          4,5
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          Furosemide
         </a>
         is our diuretic of choice for these patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          Furosemide
         </a>
         – We give furosemide orally or intravenously (IV), in the following doses:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Orally – We start with 2 mg/kg once or twice daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         IV – We start with 1 to 2 mg/kg/dose and give a second dose after six hours, if needed, to a maximum dose of 6 mg/kg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Close monitoring of the patient’s vital signs (ie, tachycardia, hypotension) and serum electrolyte levels is required because ongoing oral use of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         may cause hypovolemia and hypokalemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12556" href="/z/d/drug information/12556.html" rel="external">
          Amiloride
         </a>
         – Amiloride is a potassium-sparing diuretic that decreases sodium channel activity of the cortical collecting tubule. It can be used in combination with
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         to counter the risk of hypokalemia. The rationale for its use is that renal sodium retention is at least in part related to an activation of the epithelial sodium channel, which is inhibited by amiloride [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thiazide diuretics
         </strong>
         – Thiazide diuretics such as
         <a class="drug drug_pediatric" data-topicid="12604" href="/z/d/drug information/12604.html" rel="external">
          metolazone
         </a>
         , in combination with
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         , appear to enhance the natriuretic and diuretic effects of furosemide alone [
         <a href="#rid8">
          8
         </a>
         ]. However, this combination of diuretics is associated with hypokalemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1692721213">
         <span class="h3">
          Patients with edema and intravascular hypovolemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with any degree of edema (including anasarca, or generalized and massive edema) and evidence of intravascular hypovolemia (ie, tachycardia, peripheral vasoconstriction, oliguria, FENa &lt;0.2 percent), we give IV albumin and
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         , as follows [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We start with an IV infusion of salt-poor albumin, 0.5 to 1 g/kg given over four hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We give IV
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         at 1 mg/kg per dose in the middle and/or at the end of the albumin perfusion [
         <a href="#rid9">
          9,10
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Affected children may be intravascularly volume depleted and aggressive diuresis may lead to further volume depletion, thereby possibly precipitating acute renal failure and increasing the risk of thrombosis in this already susceptible group of patients [
         <a href="#rid11">
          11,12
         </a>
         ]. Rarely, diuretics can contribute to severe volume depletion that results in hypovolemic shock [
         <a href="#rid13">
          13
         </a>
         ]. Because of the potential for serious complications, diuretic management should be supervised by a nephrologist who has expertise in treating children with NS. (See
         <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">
          "Complications of nephrotic syndrome in children", section on 'Hypovolemia'
         </a>
         .)
        </p>
        <p>
         For patients with anasarca, treatment with
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         (1 to 2 mg/kg per dose) and salt-poor albumin (0.5 to 1 g/kg infused over four hours) should be considered with caution due to the risk of severe complications, such as pulmonary edema, hypertension, or congestive heart failure [
         <a href="#rid14">
          14,15
         </a>
         ]. A careful assessment of the patient's intravascular status is necessary before prescribing an albumin infusion [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">
          "Complications of nephrotic syndrome in children", section on 'Anasarca'
         </a>
         .)
        </p>
        <p>
         In a study of 30 children with NS and severe edema, a fractional excretion of sodium (FENa) value &lt;0.2 percent identified patients with severe edema and volume contraction who also had higher serum renin, aldosterone, and antidiuretic hormone [
         <a href="#rid5">
          5
         </a>
         ]. Diuretic therapy alone was used successfully in 10 of 11 patients with FENa &gt;0.2 percent. In one patient with an elevated FENa, albumin was added to diuretic therapy because of a rise in serum creatinine and the development of hyponatremia. (See
         <a class="medical medical_review" href="/z/d/html/7219.html" rel="external">
          "Fractional excretion of sodium, urea, and other molecules in acute kidney injury"
         </a>
         .)
        </p>
        <p>
         Albumin raises the intravascular oncotic pressure and thereby protects the intravascular compartment against volume contraction. Albumin infusion also increases protein-binding of
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         , which improves the rate of delivery to the kidney resulting in increased renal salt excretion. (See
         <a class="medical medical_review" href="/z/d/html/3044.html" rel="external">
          "Pathophysiology and treatment of edema in adults with the nephrotic syndrome", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
         Data evaluating the benefit of albumin and
         <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">
          furosemide
         </a>
         are limited and of low quality [
         <a href="#rid10">
          10
         </a>
         ]. In a retrospective study, albumin and furosemide therapy in children with NS effectively removed fluid with a mean loss of 0.4 kg (1.2 percent of body weight) per infusion [
         <a href="#rid14">
          14
         </a>
         ]. However, the effect is transient and can be associated with complications resulting from increased vascular volume, including hypertension and respiratory distress. As a result, aggressive diuresis with albumin and furosemide therapy should be reserved for patients with anasarca who have respiratory compromise due to ascites and/or pleural effusions, severe scrotal edema, peritonitis, or severe tissue breakdown [
         <a href="#rid11">
          11,17
         </a>
         ]. Other measures, such as salt and fluid restriction, are needed to prevent reaccumulation of fluid. (See
         <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">
          "Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Fluid restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is debate on the role of fluid restriction, initial restriction of fluid intake to an equivalent volume of the patient's insensible losses plus his/her urine output will result in stabilizing the patient's weight without further accumulation of edema. In patients with hyponatremia with a serum sodium of less than 135 mEq/L, fluid restriction is required as fluid accumulation is a result of inappropriate antidiuretic hormone secretion, secondary to intravascular volume depletion.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          HYPERCOAGULABILITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nephrotic patients with severe hypoalbuminemia are at risk for thromboembolic complications. Patients with infections have a higher risk of venous thromboembolism [
         <a href="#rid18">
          18
         </a>
         ]. Preventive measures include avoidance of immobilization, regular ambulation, compression stockings, avoidance of hemoconcentration resulting from hypovolemia, avoidance of central venous catheter if possible, and early treatment of sepsis or volume depletion [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">
          "Complications of nephrotic syndrome in children", section on 'Thromboembolism'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">
          "Hypercoagulability in nephrotic syndrome", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         Most clinicians do not give prophylactic anticoagulation or antiplatelet treatment initially. This is due in large part to the lack of randomized trials to determine the efficacy and safety of such an approach [
         <a href="#rid21">
          21
         </a>
         ]. However, it is important to assess the risk profile for thromboembolic complications including a known familial thrombophilic predisposition or a previous thrombotic event. In some centers, prophylactic low molecular weight heparin is given to high-risk patients including adolescents (&gt;12 years of age) who have additional risk factors including a serum albumin concentration of less than 2 g/dL (20 g/L), a fibrinogen level of more than 6 g/L, or an antithrombin III level less than 70 percent of normal, although there is no evidence that it is beneficial [
         <a href="#rid19">
          19,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H608308913">
         <span class="h2">
          Treatment of venous thromboembolism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticoagulation is most often initiated with low molecular weight heparin, such as
         <a class="drug drug_pediatric" data-topicid="13270" href="/z/d/drug information/13270.html" rel="external">
          enoxaparin
         </a>
         . Neonates and infants may require doses as high as 3 mg/kg given every 12 hours, while older children generally need only 1 mg/kg given every 12 hours [
         <a href="#rid23">
          23
         </a>
         ]. It can be given subcutaneously (avoiding the need for central venous catheterization), and its pharmacokinetic profile is more predictable than
         <a class="drug drug_pediatric" data-topicid="13349" href="/z/d/drug information/13349.html" rel="external">
          unfractionated heparin
         </a>
         . Antifactor Xa assay is used for therapeutic drug monitoring. In situations where short half-life and reversible anticoagulation is necessary, unfractionated heparin is utilized. The heparin dose necessary to obtain a therapeutic effect is often greater than normal due to decreased antithrombin III level.
         <a class="drug drug_pediatric" data-topicid="12886" href="/z/d/drug information/12886.html" rel="external">
          Warfarin
         </a>
         treatment is given for long-term treatment, as anticoagulation should be continued for a minimum three- to six-month course [
         <a href="#rid1">
          1
         </a>
         ]. Thrombolysis is reserved only for severe cases with life- or limb-threatening thromboembolism. In patients with previous thromboembolic complications, we will start treatment anticoagulation therapy if the patient remains nephrotic, which places them at continued risk for thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">
          "Hypercoagulability in nephrotic syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          INFECTION
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Bacterial
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogens of concern
         </strong>
         – Nephrotic children are at increased risk of developing infection (eg, peritonitis, pneumonia, and sepsis) due to encapsulated bacteria [
         <a href="#rid24">
          24-26
         </a>
         ]. The most common pathogen is
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         followed by
         <em>
          Escherichia
         </em>
         <em>
          coli
         </em>
         and
         <em>
          Hemophilus
         </em>
         . NS increases the susceptivity to infection because of reduced serum concentrations of immunoglobulin G, decreased complement opsonins, decreased cellular immunity, and the administration of immunosuppressive therapy. (See
         <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">
          "Complications of nephrotic syndrome in children", section on 'Bacterial infection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Initial therapy of suspected infection includes cultures and the administration of empiric broad-spectrum antibiotics based on the site of infection [
         <a href="#rid1">
          1,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, children with nephrotic syndrome who have abdominal pain and fever should undergo diagnostic paracentesis to evaluate for peritonitis [
         <a href="#rid2">
          2
         </a>
         ]. Empiric treatment of bacterial peritonitis includes intravenous antibiotics that are active against
         <em>
          S
         </em>
         .
         <em>
          pneumoniae
         </em>
         (eg, third-generation cephalosporins). Antibiotic therapy is modified based on culture results, including antimicrobial sensitives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Vaccination is the mainstay of prevention. Prophylactic antimicrobials are not recommended [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children with nephrotic syndrome should receive standard childhood immunizations at the appropriate age to reduce the risk of bacterial infections  (
         <a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef58209" href="/z/d/graphic/58209.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">
          "Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additionally, nephrotic syndrome is a high-risk condition that warrants
         <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">
          PPSV23
         </a>
         in addition to PCV for pneumococcal vaccination. We recommend PPSV23 in children with nephrotic syndrome even though antibody response may be blunted and even among those who are steroid dependent. Specific recommendations on pneumococcal vaccination in high-risk children, including those with nephrotic syndrome, are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although vaccines are ideally administered when the child is in remission and off of daily corticosteroid therapy in order to maximize the vaccine response, children who received immunization at the onset of their NS while on high-dose daily
         <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">
          prednisone
         </a>
         had good response, with a 10-fold increase in antibody levels to
         <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">
          PPSV23
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ]. Nevertheless, pneumococcal infection despite vaccination has been reported in patents with nephrotic syndrome [
         <a href="#rid28">
          28,29
         </a>
         ]. This may be because anti-pneumococcal antibody levels decrease more rapidly in children with NS as compared with healthy children [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Varicella
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with NS who require immunosuppressive therapy are at increased risk for developing varicella.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Varicella vaccination
         </strong>
         – Varicella vaccination has been shown to be effective in children with NS, and should be given to all patients with negative varicella titers [
         <a href="#rid32">
          32
         </a>
         ]. It is ideally administered as a two-dose regimen when the child is in remission and on low-dose alternate days (eg, less than 2 mg/kg of body weight on alternate days) or off of corticosteroid therapy. (See
         <a class="medical medical_review" href="/z/d/html/8275.html" rel="external">
          "Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Schedules in the United States'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Varicella exposure, immunosuppression, and no immunity
         </strong>
         – In cases of exposure in patients who are receiving immunosuppressive therapy and do not have immunity to varicella, postexposure prophylaxis consists of
         <a class="drug drug_pediatric" data-topicid="12954" href="/z/d/drug information/12954.html" rel="external">
          varicella-zoster immune globulin
         </a>
         . Timing and dosing of varicella-zoster immune globulin, subsequent monitoring, and consideration of subsequent vaccination are discussed in detail elsewhere. Antiviral postexposure prophylaxis is an alternative when varicella-zoster immune globulin cannot be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of varicella
         </strong>
         – We suggest antiviral therapy for children with nephrotic syndrome who develop primary varicella infection; for patients receiving immunosuppressive therapy, we suggest intravenous
         <a class="drug drug_pediatric" data-topicid="13247" href="/z/d/drug information/13247.html" rel="external">
          acyclovir
         </a>
         [
         <a href="#rid20">
          20
         </a>
         ]. Details on administration are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8336.html" rel="external">
          "Treatment of varicella (chickenpox) infection", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H612171066">
         <span class="h2">
          Influenza and COVID-19 vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Annual influenza vaccination and vaccination against coronavirus disease 2019 (COVID-19) are recommended for all children six months and older, including children with NS  (
         <a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef58209" href="/z/d/graphic/58209.html" rel="external">
          figure 2
         </a>
         ). Children with nephrotic syndrome who are immunocompromised or are taking immunosuppressive therapy should receive the
         <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">
          inactivated influenza vaccine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/5960.html" rel="external">
          "Seasonal influenza in children: Prevention with vaccines", section on 'Immunocompromised children'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines", section on 'Dose and interval (for immunocompetent individuals)'
         </a>
         .)
        </p>
        <p>
         In a small case series of children with NS, an adequate antibody response to influenza A vaccine was observed and maintained for six months [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         These vaccinations are generally effective even during frank NS; they help to attenuate or prevent the viral infections, as well as NS relapses that can be triggered by the infection. These benefits greatly outweigh the very minimal risk of vaccine-related relapses [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H541562383">
         <span class="h1">
          ENHANCED APPETITE AND EXCESSIVE WEIGHT GAIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased caloric consumption as a result of appetite stimulation of corticosteroid therapy can lead to excessive weight gain. Dietary measures that limit excessive caloric consumption, including a low-fat diet, will help children avoid large weight gains.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          PREVENTION OF METABOLIC BONE DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abnormalities in bone histology can be seen in patients with NS, primarily due to two processes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of vitamin D-binding protein – In children with NS, urinary loss of vitamin D binding protein may result in low ionized calcium and 25-OH vitamin D3 (25-hydroxycholecalciferol) concentrations [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prolonged corticosteroid therapy may lead to abnormalities in bone histology [
         <a href="#rid37">
          37
         </a>
         ] and, subsequently, osteoporosis [
         <a href="#rid38">
          38
         </a>
         ]. However, one study using dual-energy x-ray absorptiometry did not find any difference in spinal or whole body mineral content of glucocorticoid-treated children with NS compared with control patients [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Based on the above, calcium (500 mg/day) and vitamin D (2000 to 4000 units) supplements often are prescribed, especially when there are documented low calcium and/or vitamin D concentrations; however, there are currently no data that have shown this intervention to be effective.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          DYSLIPIDEMIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dyslipidemia is common in children with persistent
         <em>
         </em>
         NS and is a risk factor for accelerated atherosclerosis, myocardial infarction, and stroke and may play a role in the progression of chronic renal failure  (
         <a class="graphic graphic_figure graphicRef130871" href="/z/d/graphic/130871.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]. The lipid abnormalities induced by the NS reverse with remission. For children who remain persistently nephrotic and have hyperlipidemia, the approach to pharmacotherapy depends on the low-density lipoprotein (LDL) cholesterol level and presence of other risk factors for cardiovascular disease. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">
          "Dyslipidemia in children and adolescents: Management", section on 'Hypercholesterolemia'
         </a>
         .)
        </p>
        <p>
         The optimal treatment of hyperlipidemia in children with persistent NS is unknown [
         <a href="#rid41">
          41
         </a>
         ]. In children with NS, statin therapy based on limited short-term observational data are effective and safe in reducing total and LDL cholesterol, and triglyceride levels [
         <a href="#rid42">
          42
         </a>
         ]. Nevertheless, statins should be used with caution until controlled studies are performed [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Data from adults with persistent proteinuria demonstrate the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary modification has been shown to have little benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most successful hypolipidemic agents with persistent NS are the statins [
         <a href="#rid43">
          43,44
         </a>
         ]. These agents generally produce few side effects and can lower the plasma total and LDL cholesterol concentrations by 20 to 45 percent. There is a smaller reduction in triglyceride levels.
        </p>
        <p>
        </p>
        <p>
         LDL apheresis with steroid therapy has been proposed in patients with hyperlipidemia and refractory NS. In one study involving 11 children, this treatment resulted in complete remission in five and partial remission in two patients [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         A more complete discussion on the treatment of hyperlipidemia in adults with NS is found separately. (See
         <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">
          "Lipid abnormalities in nephrotic syndrome", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1498766394">
         <span class="h1">
          HYPOTHYROIDISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with persistent NS may develop hypothyroidism due to the urinary loss of free and protein-bound thyroid hormones [
         <a href="#rid46">
          46,47
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          Levothyroxine
         </a>
         is given to patients with hypothyroidism defined by a high serum thyroid-stimulating hormone levels (&gt;10mU/L) and low thyroxine (T4) and triiodothyronine (T3) [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">
          "Acquired hypothyroidism in childhood and adolescence", section on 'Treatment and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          HYPERTENSION AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with NS and persistent hypertension are more likely to have chronic kidney disease with poor outcome. In addition, hypertension is a major risk factor for cardiovascular disease. As a result, antihypertensive therapy is given to children with chronic kidney disease, including those with NS, to reduce blood pressure  (
         <a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">
          "Nonemergent treatment of hypertension in children and adolescents", section on 'Target blood pressure goals'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">
          "Chronic kidney disease in children: Complications", section on 'Hypertension'
         </a>
         .)
        </p>
        <p>
         For children with NS and hypertension, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are the preferred anti-hypertensive agents because of their potential additive antiproteinuric benefit and ability to slow progression of renal impairment. The maximal antiproteinuric effect is observed after four weeks [
         <a href="#rid49">
          49
         </a>
         ]; the antiproteinuric effect can be increased by low salt diet and/or diuretics [
         <a href="#rid50">
          50
         </a>
         ]. ACE inhibitors and ARBs should be terminated if hyperkalemia cannot be controlled or the plasma creatinine concentration increases more than 30 percent above the baseline value. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
         Other antihypertensive agents that have been used in children with NS include beta blockers and calcium channel blockers. (See
         <a class="medical medical_review" href="/z/d/html/6131.html" rel="external">
          "Nonemergent treatment of hypertension in children and adolescents", section on 'Management approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2819525005">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110405.html" rel="external">
          "Society guideline links: Nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of symptomatic management
         </strong>
         – The majority of children with nephrotic syndrome (NS)will respond to steroid therapy. However, symptomatic management is important in the early course of therapy as response to steroid therapy may take several weeks and it is the mainstay of therapy in children who fail to respond to steroids. (See
         <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">
          "Treatment of idiopathic nephrotic syndrome in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypovolemia
         </strong>
         – In patients with significant signs or symptoms of decreased intravascular volume, an albumin infusion may be used to restore intravascular volume (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hypovolemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Edema
         </strong>
         – In patients with persistent proteinuria, salt and fluid restriction as well as diuretics (alone or in combination with salt-poor albumin) are used to control edema. (See
         <a class="local">
          'Edema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reducing thromboembolic risk
         </strong>
         – Preventive measures to avoid thromboembolic complication include mobilization, avoidance of hemoconcentration resulting from hypovolemia, and early treatment of sepsis or volume depletion. We suggest not using routine prophylactic anticoagulation therapy in children with NS (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Hypercoagulability'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">
          "Hypercoagulability in nephrotic syndrome", section on 'Prevention of thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reducing infectious risk
         </strong>
         – Children with NS are at increased risk for both bacterial and viral infections. They should receive standard childhood immunizations at the appropriate age to reduce the risk of such infections  (
         <a class="graphic graphic_figure graphicRef82617" href="/z/d/graphic/82617.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef58209" href="/z/d/graphic/58209.html" rel="external">
          figure 2
         </a>
         ). Additionally, for pneumococcal vaccination, nephrotic syndrome is a high-risk condition that warrants
         <a class="drug drug_pediatric" data-topicid="12948" href="/z/d/drug information/12948.html" rel="external">
          PPSV23
         </a>
         in addition to pneumococcal conjugate vaccine (PCV). (See
         <a class="local">
          'Infection'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6053.html" rel="external">
          "Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dyslipidemia
         </strong>
         – The optimal treatment of hyperlipidemia in children with persistent NS is unknown. For children who remain persistently nephrotic and have hyperlipidemia, the approach to pharmacotherapy depends on the low-density lipoprotein (LDL) cholesterol level and presence of other risk factors for cardiovascular disease. This is discussed in detail elsewhere. (See
         <a class="local">
          'Dyslipidemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">
          "Dyslipidemia in children and adolescents: Management", section on 'Hypercholesterolemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothyroidism
         </strong>
         – This is a complication of persistent pediatric NS. We recommend administration of synthetic thyroxine (
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         ) for patients with high serum thyroid-stimulating hormone levels and low thyroxine (T4) and triiodothyronine (T3) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">
          "Acquired hypothyroidism in childhood and adolescence", section on 'Treatment and prognosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension
         </strong>
         – Children with NS and persistent hypertension are more likely to have chronic kidney disease with poor outcome. In these patients, we suggest that angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) be used to treat their hypertension because of their potential additive antiproteinuric benefit and ability to slow progression of renal impairment (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Hypertension and angiotensin-converting enzyme inhibitors'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           McCaffrey J, Lennon R, Webb NJ. The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol 2016; 31:1383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2023; 38:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020; 35:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vande Walle JG, Donckerwolcke RA. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol 2001; 16:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study. Clin J Am Soc Nephrol 2009; 4:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deschênes G, Wittner M, Stefano A, et al. Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. J Am Soc Nephrol 2001; 12:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doucet A, Favre G, Deschênes G. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications. Pediatr Nephrol 2007; 22:1983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garin EH. A comparison of combinations of diuretics in nephrotic edema. Am J Dis Child 1987; 141:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadnapaphornchai MA, Tkachenko O, Shchekochikhin D, Schrier RW. The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications. Pediatr Nephrol 2014; 29:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedin E, Bijelić V, Barrowman N, Geier P. Furosemide and albumin for the treatment of nephrotic edema: a systematic review. Pediatr Nephrol 2022; 37:1747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogg RJ, Portman RJ, Milliner D, et al. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan MJ 3rd, Hough DR, Agodoa LC. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J 1983; 76:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamauchi H, Hopper J Jr. Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. Report of ten cases. Ann Intern Med 1964; 60:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 1993; 91:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid CJ, Marsh MJ, Murdoch IM, Clark G. Nephrotic syndrome in childhood complicated by life threatening pulmonary oedema. BMJ 1996; 312:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallash M, Mahan JD. Mechanisms and management of edema in pediatric nephrotic syndrome. Pediatr Nephrol 2021; 36:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welch TR, Gianis J, Sheldon CA. Perforation of the scrotum complicating nephrotic syndrome. J Pediatr 1988; 113:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter SL, Goldman J, Sherman AK, et al. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol 2019; 34:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerlin BA, Haworth K, Smoyer WE. Venous thromboembolism in pediatric nephrotic syndrome. Pediatr Nephrol 2014; 29:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. Pediatrics 2009; 124:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol 2012; 7:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffini L, Trimarchi T, Beliveau J, Davis D. Thromboprophylaxis in a pediatric hospital: a patient-safety and quality-improvement initiative. Pediatrics 2011; 127:e1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerlin BA. Current and future management of pediatric venous thromboembolism. Am J Hematol 2012; 87 Suppl 1:S68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre P, Craig JC. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health 1998; 34:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liponski I, Cochat P, Gagnadoux MF, et al. [Bacterial complications of nephrotic syndrome in children]. Presse Med 1995; 24:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasini A, Aceto G, Ammenti A, et al. Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality. Pediatr Nephrol 2015; 30:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulinski T, Leroy S, Dubrel M, et al. High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone. Pediatr Nephrol 2008; 23:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Primack WA, Rosel M, Thirumoorthi MC, et al. Failure of pneumococcal vaccine to prevent Streptococcus pneumoniae sepsis in nephrotic children. Lancet 1979; 2:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore DH, Shackelford PG, Robson AM, Rose GM. Recurrent pneumococcal sepsis and defective opsonization after pneumococcal capsular polysaccharide vaccine in a child with nephrotic syndrome. J Pediatr 1980; 96:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spika JS, Halsey NA, Le CT, et al. Decline of vaccine-induced antipneumococcal antibody in children with nephrotic syndrome. Am J Kidney Dis 1986; 7:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Güven AG, Akman S, Bahat E, et al. Rapid decline of anti-pneumococcal antibody levels in nephrotic children. Pediatr Nephrol 2004; 19:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furth SL, Arbus GS, Hogg R, et al. Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group. J Pediatr 2003; 142:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poyrazoğlu HM, Düşünsel R, Gündüz Z, et al. Antibody response to influenza A vaccination in children with nephrotic syndrome. Pediatr Nephrol 2004; 19:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee S, Dissanayake PV, Abeyagunawardena AS. Vaccinations in children on immunosuppressive medications for renal disease. Pediatr Nephrol 2016; 31:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angeletti A, Lugani F, La Porta E, et al. Vaccines and nephrotic syndrome: efficacy and safety. Pediatr Nephrol 2023; 38:2915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng FL, Shults J, Herskovitz RM, et al. Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission. Pediatr Nephrol 2005; 20:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freundlich M, Jofe M, Goodman WG, Salusky IB. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol 2004; 19:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease? Am J Kidney Dis 2003; 41:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonard MB, Feldman HI, Shults J, et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004; 351:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018; 14:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol 2020; 35:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prescott WA Jr, Streetman DA, Streetman DS. The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome. Ann Pharmacother 2004; 38:2105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996; 10:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997; 130:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan A, Cleper R, Krause I, et al. Hypothyroidism in children with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2012; 27:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito S, Kano K, Ando T, Ichimura T. Thyroid function in children with nephrotic syndrome. Pediatr Nephrol 1994; 8:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigone MC, Capalbo D, Weber G, Salerno M. Mild Hypothyroidism in Childhood: Who, When, and How Should Be Treated? J Endocr Soc 2018; 2:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gansevoort RT, de Zeeuw D, de Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993; 44:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6113 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26556028" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The non-immunosuppressive management of childhood nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36269406" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32382828" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11322379" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pathogenesis of edema formation in the nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19406963" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181809" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554565" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3296741" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A comparison of combinations of diuretics in nephrotic edema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23989393" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The nephrotic syndrome: pathogenesis and treatment of edema formation and secondary complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35239032" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Furosemide and albumin for the treatment of nephrotic edema: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10835064" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6410516" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14114444" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hypovolemic shock and hypotension as a complication in the nephrotic syndrome. Report of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8502517" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Efficacy of albumin and diuretic therapy in children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8555860" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nephrotic syndrome in childhood complicated by life threatening pulmonary oedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33216218" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mechanisms and management of edema in pediatric nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3397797" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Perforation of the scrotum complicating nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30194664" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23812352" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Venous thromboembolism in pediatric nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19651590" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of childhood onset nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22344511" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21464186" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Thromboprophylaxis in a pediatric hospital: a patient-safety and quality-improvement initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22367975" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Current and future management of pediatric venous thromboembolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9727168" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prevention of serious bacterial infection in children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7899329" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : [Bacterial complications of nephrotic syndrome in children].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25127916" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18324419" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/91924" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Failure of pneumococcal vaccine to prevent Streptococcus pneumoniae sepsis in nephrotic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7365596" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Recurrent pneumococcal sepsis and defective opsonization after pneumococcal capsular polysaccharide vaccine in a child with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3717153" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Decline of vaccine-induced antipneumococcal antibody in children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14648335" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rapid decline of anti-pneumococcal antibody levels in nephrotic children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12584535" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Varicella vaccination in children with nephrotic syndrome: a report of the Southwest Pediatric Nephrology Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14648340" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antibody response to influenza A vaccination in children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26450774" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vaccinations in children on immunosuppressive medications for renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36512075" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vaccines and nephrotic syndrome: efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15602667" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vitamin D insufficiency in steroid-sensitive nephrotic syndrome in remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14991389" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12776267" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15329424" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29176657" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31302760" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Dyslipidemia and cardiovascular health in childhood nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507504" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8703704" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9063427" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14655182" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22167590" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hypothyroidism in children with steroid-resistant nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7947028" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Thyroid function in children with nephrotic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30187015" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Mild Hypothyroidism in Childhood: Who, When, and How Should Be Treated?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8231031" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2550696" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
